Arcus makes its HIF2α pitch
After living in the shadow of Arcus’s TIGIT project, casdatifan might soon come into its own.
After living in the shadow of Arcus’s TIGIT project, casdatifan might soon come into its own.
The Merck & Co drug's first successful phase 3 study might not be all it’s cracked up to be.